Vertex Pharmaceuticals jumps 7% after rival's drug trial fails to meet key goals

Stock News08-10 23:48

U.S. stock markets saw notable moves on Monday, with Vertex Pharmaceuticals (VRTX.US) surging nearly 7% in early trading to hit an all-time high. In contrast, competitor Sionna Therapeutics (SION.US) plunged more than 90%, reaching a record low.

This sharp divergence in stock performance came after Sionna announced that it would discontinue its experimental cystic fibrosis drug, SION-719, following a mid-stage clinical trial failure. The drug did not meet its primary endpoint, prompting the company to halt further development.

Investors had previously worried that Sionna's drug could pose a threat to Vertex Pharmaceuticals' core cystic fibrosis business. However, the trial's failure has alleviated those concerns. Vertex Pharmaceuticals markets Trikafta and Alyftrek for treating cystic fibrosis, a rare, chronic, and life-shortening genetic disease that causes progressive lung damage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment